191 related articles for article (PubMed ID: 25418598)
1. [Plasma cell leukemia].
Ravinet A; Bay JO; Tournilhac O
Bull Cancer; 2014 Nov; 101(11):1048-58. PubMed ID: 25418598
[TBL] [Abstract][Full Text] [Related]
2. Plasma cell leukemia: concepts and management.
Liedtke M; Medeiros BC
Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
[TBL] [Abstract][Full Text] [Related]
3. How I treat plasma cell leukemia.
van de Donk NW; Lokhorst HM; Anderson KC; Richardson PG
Blood; 2012 Sep; 120(12):2376-89. PubMed ID: 22837533
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and treatment for plasma cell leukemia].
Miwa A
Nihon Rinsho; 2012 Apr; 70 Suppl 2():628-41. PubMed ID: 23134023
[No Abstract] [Full Text] [Related]
6. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.
Nishihori T; Abu Kar SM; Baz R; Alsina M; Harousseau JL; Kharfan-Dabaja MA
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1144-51. PubMed ID: 23416092
[TBL] [Abstract][Full Text] [Related]
7. Plasma cell leukaemia and other aggressive plasma cell malignancies.
Sher T; Miller KC; Deeb G; Lee K; Chanan-Khan A
Br J Haematol; 2010 Aug; 150(4):418-27. PubMed ID: 20701603
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
Mattei D; Mordini N; Vigna Taglianti R; Bruno B; Rapezzi D; Gallamini A
Haematologica; 2005 Jun; 90(6):861-2. PubMed ID: 15951306
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.
Lebovic D; Zhang L; Alsina M; Nishihori T; Shain KH; Sullivan D; Ochoa-Bayona JL; Kharfan-Dabaja MA; Baz R
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):507-11. PubMed ID: 21813352
[TBL] [Abstract][Full Text] [Related]
10. [Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis].
Jurczyszyn A; Zawirska D; Skotnicki AB
Przegl Lek; 2011; 68(6):320-5. PubMed ID: 22039670
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma.
Laubach J; Richardson P; Anderson K
Annu Rev Med; 2011; 62():249-64. PubMed ID: 21090965
[TBL] [Abstract][Full Text] [Related]
12. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
13. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R
Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell leukemia: from biology to treatment.
Jelinek T; Kryukov F; Rihova L; Hajek R
Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
[TBL] [Abstract][Full Text] [Related]
16. [Plasma cell leukemia: three case-reports and review of literature].
Eddou H; Mahtat el M; Zahid H; Maaroufi HE; Jennane S; Messaoudi N; Doghmi K; Mikdame M
Ann Biol Clin (Paris); 2013; 71(6):698-702. PubMed ID: 24342791
[TBL] [Abstract][Full Text] [Related]
17. Plasma Cell Leukemia – the Forgotten Disease.
Žárska M; Vrábel D; Bezdekova R; Štork M; Jarošová M; Adam Z; Krejčí M; Pour L; Ševčíková S
Klin Onkol; 2019; 32(1):40-46. PubMed ID: 30764628
[TBL] [Abstract][Full Text] [Related]
18. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of chromosomal aberrations in multiple myeloma.
Nahi H; Sutlu T; Jansson M; Alici E; Gahrton G
J Intern Med; 2011 Feb; 269(2):137-47. PubMed ID: 21158983
[TBL] [Abstract][Full Text] [Related]
20. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
